Efficient Delivery to the Lungs of Flunisolide Aerosol From a New Portable Hand-Held Multidose Nebulizer

doi:10.1021/js950522q

Journal of Pharmaceutical Sciences

Volume 85, Issue 9, September 1996, Pages 960-964

https://doi.org/10.1021/js950522q Get rights and content

Abstract

In order to provide asthmatic patients with an inhaler that does not use chlorofluorocarbon propellants, a novel multidose hand-held nebulizer (RESPIMAT, Boehringer Ingelheim Ltd.) has been developed. This device delivers 200 ×15 µL metered doses of drug solution, but does not use propellants of any kind. In this study of 10 healthy volunteers, the deposition pattern in the lungs and oropharynx of an ethanolic solution of flunisolide delivered via a prototype III multidose nebulizer has been determined by γ scintigraphy. A comparison was made with the same dose (250 µg) of flunisolide delivered by a pressurized metered dose inhaler (MDI) and MDI plus Inhacort spacer. Mean (SD) whole lung deposition from the multidose nebulizer (39.7 (9.9) % of the metered dose) was significantly higher than that from either MDI (15.3 (5.1) %, P < 0.01) or MDI plus spacer (28.0 (7.0) %, P = 0.01). A mean 10.4% of the dose was recovered from an exhaled air filter for the multidose nebulizer, but less than 2% of the dose for MDI or MDI plus spacer. Oropharyngeal deposition was significantly reduced for the multidose nebulizer (39.9 (9.4) %) compared to MDI (66.9 (7.1) %), but was reduced further for the MDI plus spacer (27.3 (11.3) %). The multidose nebulizer delivers an unusually high percentage of an aerosol dose to the lungs, and it "targets" flunisolide to the lungs more effectively than the MDI. The multidose nebulizer could constitute a viable alternative to MDIs in asthma maintenance therapy.

References and Notes (33)

M.B. Dolovich et al.
Chest
(1983)
M.T. Vidgren et al.
Int. J. Pharm.
(1987)
S.P. Newman et al.
Int. J. Pharm.
(1991)
K.J. Harnor et al.
Int. J. Pharm.
(1993)
L. Borgström et al.
Int. J. Pharm.
(1993)
P.M. Holzner et al.
Int. J. Pharm.
(1994)
G. Hooper et al.
Respir. Med.
(1995)
S.P. Newman et al.
Thorax
(1989)
P.J. Barnes et al.
Am. Rev. Respir. Dis.
(1993)
J.H. Toogood et al.
Am. Rev. Respir. Dis.
(1984)

P.H. Brown et al.

Thorax

(1990)

S.P. Newman

Eur. Respir. J.

(1990)

B. Zierenberg et al.

P.H. Quanjer et al.

Eur. Respir. J.

(1993)

S.P. Newman et al.

Thorax

(1991)

United States Pharmacopeia. Pharm. Forum.

(1993)

Cited by (94)

Inhalation drug delivery in combating pulmonary infections: Advances and challenges
2023, Journal of Drug Delivery Science and Technology
Pulmonary infections (PIs) are contributing as a significant cause of mortality across the world. The clinical applications of a variety of therapeutics approved for PIs have been limited owing to their fatal side effects and inappropriate route of administration. The aforesaid drawbacks can be conquered via the inhalation delivery of therapeutics. Inhalation drug delivery can be a promising approach for targeting PIs. This approach can deliver drugs to the target site and minimize toxicity. However, types of barriers are the chief hurdle to inhalation drug delivery. The nanoparticulate approach can be efficient to overcome these barriers. The various inhalable nanoparticles (NPs) such as lipidic, polymeric, hybrid lipid polymer (HLP), and metal NPs have been explored to treat PIs efficiently. Vaccines and nanovaccines have also shown promise in the prevention and treatment of PIs and can be further explored. The inhalation device is a core of inhalation drug delivery however these devices are allied with several drawbacks therefore; the apt selection of inhalation devices is of huge significance. Furthermore, very few inhalable formulations to treat PIs have been marketed and entered into clinical trials, and extensive efforts are required to bring more formulations into the market and clinical trials. In this review, the author discusses PIs overview, conventional treatment for PIs and their limitations, inhalation drug delivery benefits and challenges. Further, nanoparticulate-based inhalation drug delivery, inhalable vaccines and nanovaccines, inhalation devices, and inhaled formulations in market, and clinical trials are also discussed. In a nutshell, inhalation drug delivery can be a promising strategy to manage PIs.
In vitro-in vivo correlation of cascade impactor data for orally inhaled pharmaceutical aerosols
2021, Advanced Drug Delivery Reviews
Citation Excerpt :
A simple approach to investigating and establishing an IVIVC is to evaluate the effects of different in vitro factors in cascade impactor experiments and compare the results with human lung deposition data reported in the literature. Many pulmonary scintigraphy studies using various inhaler devices have been published [36–46]. The primary endpoints of these studies were often to compare drug delivery between different inhaler devices in different subjects.
In vitro-in vivo correlation is the establishment of a predictive relationship between in vitro and in vivo data. In the context of cascade impactor results of orally inhaled pharmaceutical aerosols, this involves the linking of parameters such as the emitted dose, fine particle dose, fine particle fraction, and mass median aerodynamic diameter to in vivo lung deposition from scintigraphy data. If the dissolution and absorption processes after deposition are adequately understood, the correlation may be extended to the pharmacokinetics and pharmacodynamics of the delivered drugs. Correlation of impactor data to lung deposition is a relatively new research area that has been gaining recent interest. Although few in number, experiments and meta-analyses have been conducted to examine such correlations. An artificial neural network approach has also been employed to analyse the complex relationships between multiple factors and responses. However, much research is needed to generate more data to obtain robust correlations. These predictive models will be useful in improving the efficiency in product development by reducing the need of expensive and lengthy clinical trials.
Optimizing drug delivery in COPD: The role of inhaler devices
2017, Respiratory Medicine
Citation Excerpt :
Clinical studies support this finding by demonstrating that a considerably smaller dose of a bronchodilator, compared with the pMDIs, results in the same level of efficacy and safety. Moreover, improved lung deposition of the drug aerosols from the Respimat® has been demonstrated by using radiolabeled drug particles and gamma scintigraphy [69–71]. However, the metered volume of 15 μL limits the dose delivery capacity of the marketed design exclusively to drugs with high solubility with respect to the required dose.
Inhaled medication is the cornerstone of the pharmacological treatment for patients with asthma and chronic obstructive pulmonary disease (COPD). Several inhaler devices exist, and each device has specific characteristics to achieve the optimal inhalation of drugs. The correct use of inhaler devices is not granted and patients may incur in mistakes when using pressurized metered-dose inhalers (pMDIs) or dry-powder inhaler (DPIs). The incorrect use of inhaler devices can lead to a poorly controlled disease status. Unfortunately, guidelines provide limited guidance regarding the choice of devices. This article presents a review of the literature on different inhaler device requirements. Data from literature (PubMed and Google Scholar) on the commercially available inhaler devices have been evaluated and the history of inhaler medicine described. Furthermore, advantages and disadvantages of each type of device have been analyzed. The evaluation of literature indicated the availability of robust data on the devices characteristics and factors influencing selection of delivery devices. Each type of device has its own pro and cons. The age, cognitive status, visual acuity, manual dexterity, manual strength and ability to coordinate the inhaler actuation with inhalation may be as important as the disease severity in determining the correct approach to delivery of respiratory medication. The administration of effective therapies via a device that is simple to use and accepted by patients may help to improve treatment outcomes in patients with COPD.
Inhaler use in chronic obstructive pulmonary disease patients: a meta-analysis
2022, Frontiers of Nursing
Nanotechnology-Assisted Metered-Dose Inhalers (MDIs) for High-Performance Pulmonary Drug Delivery Applications
2022, Pharmaceutical Research
Improving the risk-to-benefit ratio of inhaled corticosteroids through delivery and dose: current progress and future directions
2022, Expert Opinion on Drug Safety

View all citing articles on Scopus

View full text

Research ArticlesEfficient Delivery to the Lungs of Flunisolide Aerosol From a New Portable Hand-Held Multidose Nebulizer

Abstract

Chest

Int. J. Pharm.

Int. J. Pharm.

Int. J. Pharm.

Int. J. Pharm.

Int. J. Pharm.

Respir. Med.

Thorax

Am. Rev. Respir. Dis.

Am. Rev. Respir. Dis.

Thorax

Eur. Respir. J.

Eur. Respir. J.

Thorax

United States Pharmacopeia. Pharm. Forum.

Research Articles
Efficient Delivery to the Lungs of Flunisolide Aerosol From a New Portable Hand-Held Multidose Nebulizer